

20 Sep 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Roche shores up oncology; Janssen's multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 September 2021, including: [*Roche Holding AG*](#) shores up oncology; [*Janssen Pharmaceutical Cos.*](#)'s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID-19.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Roche Gives The Stage To A New Generation Of Cancer Drugs*](#)" - Scrip, 15 Sep, 2021.)

(Also see "[*Working Toward A Cure: Janssen's Multiple Myeloma Strategy*](#)" - Scrip, 13 Sep, 2021.)

(Also see "[*Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study*](#)" - Scrip, 15 Sep, 2021.)

(Also see "[*Novartis's Tislelizumab Takes First Step On US Approval Path*](#)" - Scrip, 13 Sep, 2021.)

(Also see "[*With Delta Variant Spread, Herd Immunity A 'Myth', Says Public Health Expert*](#)" - Scrip,

14 Sep, 2021.)

[Click here to explore this interactive content online](#) 